CapVest to acquire majority stake in STADA

Bain Capital and Cinven will each retain a minority stake, reflecting their ongoing confidence in STADA’s future growth

CapVest Partner, a leading global investment firm, announced it has signed a definitive agreement with Bain Capital and Cinven to acquire a majority stake in STADA Arzneimittel, a global leader in consumer healthcare, generics, and specialty pharmaceuticals.

Headquartered in Bad Vilbel, Germany, STADA has evolved under Bain Capital and Cinven’s ownership since 2017 from a traditional generics company into a diversified global healthcare platform. Today, STADA generates more than €4 billion in annual revenues, has achieved a compound annual sales growth rate of 9 per cent, more than doubled its EBITDA since 2017, and employs 11,600 people worldwide.

With a strong heritage in healthcare and a portfolio spanning consumer healthcare, generics, and specialty pharmaceuticals, STADA is well-positioned for continued global expansion. Bain Capital and Cinven will each retain a minority stake, reflecting their ongoing confidence in STADA’s future growth.

CapVest, a seasoned healthcare investor with a proven 20-year track record of building leading international businesses, plans to leverage its sector expertise and capital strength to accelerate STADA’s growth strategy both in Germany and globally.

Matthew Fargie, Partner at CapVest, commented: “We have long admired STADA’s heritage, its high-performing portfolio, and its culture of caring for people’s health. Under Peter Goldschmidt’s leadership, the company has transformed into a resilient global champion. We are excited to support STADA’s next chapter, deploying significant new capital and our healthcare expertise to accelerate growth and innovation worldwide.”

Peter Goldschmidt, CEO of STADA, said: “CapVest shares our vision of long-term value creation driven by innovation, operational excellence, and growth. Their deep expertise in healthcare makes them an ideal partner as we seize new opportunities in Consumer Healthcare, Generics, and Specialty Pharmaceuticals. We are grateful to Cinven and Bain Capital for their transformative partnership since 2017, which enabled STADA to achieve global leadership and set the stage for our ambitious next phase.”

The transaction, subject to regulatory approvals and customary closing conditions, is expected to close in early 2026.

Canson Capital Partners and Centerview Partners acted as lead financial advisors to CapVest.